Melo Junia V, Barnes David J
Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Nat Rev Cancer. 2007 Jun;7(6):441-53. doi: 10.1038/nrc2147.
Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?
慢性髓性白血病（CML）可被视为通过多步骤过程演变的肿瘤形成的范例。CML也是可通过分子疗法靶向治疗的疾病的最佳例子之一；然而，新型“设计药物”的成功很大程度上仅限于疾病的慢性期。如果在这个阶段不能治愈，CML必然会进展并转化为经历“原始细胞危象”的急性型白血病。这种转化的原因仍知之甚少。这种进展的潜在机制是什么，其他常见癌症是否也有这些机制？
